Literature DB >> 17823200

Environmental risk factors for the development of psoriatic arthritis: results from a case-control study.

E Pattison1, B J Harrison, C E M Griffiths, A J Silman, I N Bruce.   

Abstract

OBJECTIVE: To identify potential risk factors for the onset of inflammatory arthritis (IA) in a large cohort of patients with psoriatic arthritis (PsA) of recent onset.
METHODS: We recruited cases with psoriasis and an onset of IA within the past 5 years. Controls were patients who had psoriasis but no arthritis. We assessed potential factors associated with the development of IA using a detailed postal questionnaire. An unmatched analysis adjusted for age and gender was performed. Exposure was censored in the controls at a "dummy-date" assigned randomly in proportion to the percentage of cases developing IA in any given year.
RESULTS: We studied 98 cases and 163 controls. Exposures showing a positive association before the onset of IA in patients with psoriasis were: rubella vaccination (OR (95% CI) = 12.4 (1.2 to 122)), injury sufficient to require a medical consultation (2.53 (1.1 to 6.0)), recurrent oral ulcers (4.2 (2.0 to 9.0)) and moving house (2.3 (1.2 to 4.4)). Cases were also more likely to have experienced a fractured bone requiring hospital admission (50% vs 9%, p = 0.040).
CONCLUSIONS: We found a number of environmental exposures associated with the onset of IA in subjects with psoriasis. The strongest associations were with trauma thereby adding to the hypothesis of a "deep Koebner phenomenon" in PsA. Our data also suggest that exposure of the immune system to certain infection-related triggers may also be of relevance. Further studies are needed to verify these observations and to examine potential immunological mechanisms that underlie them.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17823200     DOI: 10.1136/ard.2007.073932

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  44 in total

Review 1.  The genetics of psoriasis and psoriatic arthritis.

Authors:  Vinod Chandran
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

2.  Identification of risk factors for psoriatic arthritis: scientific opportunity meets clinical need.

Authors:  Alexis Ogdie; Joel M Gelfand
Journal:  Arch Dermatol       Date:  2010-07

Review 3.  The Epidemiology of Psoriatic Arthritis.

Authors:  Alexis Ogdie; Pamela Weiss
Journal:  Rheum Dis Clin North Am       Date:  2015-09-11       Impact factor: 2.670

4.  [New aspects on the pathogenesis of psoriatic arthritis].

Authors:  A J Hueber; B Manger
Journal:  Z Rheumatol       Date:  2013-10       Impact factor: 1.372

5.  Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthritis Following Lyme Disease.

Authors:  Sheila L Arvikar; Jameson T Crowley; Katherine B Sulka; Allen C Steere
Journal:  Arthritis Rheumatol       Date:  2017-01       Impact factor: 10.995

Review 6.  Targeting IL-17 in psoriatic arthritis.

Authors:  Elizabeth A Wang; Erika Suzuki; Emanual Maverakis; Iannis E Adamopoulos
Journal:  Eur J Rheumatol       Date:  2017-11-10

7.  Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study.

Authors:  Floranne C Wilson; Murat Icen; Cynthia S Crowson; Marian T McEvoy; Sherine E Gabriel; Hilal Maradit Kremers
Journal:  Arthritis Rheum       Date:  2009-02-15

8.  What epidemiology has told us about risk factors and aetiopathogenesis in rheumatic diseases.

Authors:  Jacqueline E Oliver; Alan J Silman
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

9.  Genetics of psoriasis and psoriatic arthritis.

Authors:  Vinod Chandran
Journal:  Indian J Dermatol       Date:  2010 Apr-Jun       Impact factor: 1.494

10.  Validation of the Toronto Psoriatic Arthritis Screen II (TOPAS II) questionnaire in a Turkish population.

Authors:  Mehmet Tuncay Duruöz; Canan Şanal Toprak; Fırat Ulutatar
Journal:  Rheumatol Int       Date:  2017-11-07       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.